HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion.

Abstract
Sixty patients with metastatic breast cancer refractory to prior doxorubicin combinations were randomized by performance status, dominant disease site, and number of involved organ sites to receive vindesine either as a bolus injection of 3-4 mg/m2 iv every 10-14 days or as a continuous 5-day infusion of 1-1.2 mg/m2/day every 21 days. There were two patients with partial responses (7%) and six with stable disease among the 26 evaluable patients who received bolus injections. Of the 25 evaluable patients who received continuous infusions, seven achieved a partial response (28%) and 11 had stable disease (0.001 less than P less than 0.005). Thirteen patients, after failing to respond to bolus vindesine, were given continuous infusions. Of these, 11 were evaluable and four had partial response (36%). Responses were seen in all organ sites of involvement, with response duration ranging from 2 to 9+ months. Side effects included nausea, vomiting, stomatitis, constipation, neuropathy, fever, and myelosuppression. Except for myelosuppression, which was more evident with the continuous infusion schedule, no significant difference was seen in the frequency of side effects encountered with the two schedules. These results confirmed that there is an improved therapeutic index for vindesine when it is given as a continuous 5-day infusion.
AuthorsH Y Yap, G R Blumenschein, G P Bodey, G N Hortobagyi, A U Buzdar, A DiStefano
JournalCancer treatment reports (Cancer Treat Rep) 1981 Sep-Oct Vol. 65 Issue 9-10 Pg. 775-9 ISSN: 0361-5960 [Print] United States
PMID7273012 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Vinblastine
  • Vindesine
Topics
  • Adult
  • Aged
  • Blood Cell Count
  • Breast Neoplasms (drug therapy)
  • Drug Administration Schedule
  • Drug Evaluation
  • Female
  • Humans
  • Middle Aged
  • Nausea (chemically induced)
  • Neoplasm Metastasis
  • Prognosis
  • Random Allocation
  • Vinblastine (administration & dosage, adverse effects, analogs & derivatives)
  • Vindesine
  • Vomiting (chemically induced)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: